Exenatide Once Weekly Versus Liraglutide Once Daily in Patients With Type 2 Diabetes (DURATION-6): A Randomised, Open-Label Study

Study Questions:

What is the comparative efficacy, safety, and tolerability of the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide once weekly and liraglutide once daily in type 2 diabetic patients with inadequate glycemic control despite the prescription of lifestyle modifications and maximum/near maximum doses of oral antihyperglycemic drugs?